ALBANY, New York, Oct. 22, 2012 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Steven R. Hagen, Ph.D., has been promoted to senior vice president of pharmaceutical development and manufacturing. He will continue to report to AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. Dr. Hagen is responsible for approximately two-thirds of AMRI's contract operations, including Chemical Development, Analytical and Pharmaceutical Quality Services, Small Scale cGMP Manufacturing of active ingredients and dosage forms, and Large Scale Commercial Manufacturing. These operations encompass facilities located in Albany, Rensselaer and Syracuse, New York; Burlington, Massachusetts; Holywell, Wales (UK) and Hyderabad and Aurangabad, India.
"We are pleased to announce this promotion of Dr. Hagen," said Dr. D'Ambra. "Under Dr. Hagen's leadership, AMRI has experienced growth within key sectors of AMRI's business. Additionally, Dr. Hagen has overseen the continued expansion and adherence to world class compliance programs and milestones, as well as the consistent attainment of operating performance metrics in AMRI's manufacturing area."
Dr. D'Ambra continued, "Steve has surrounded himself with a first class team and together they have continued to drive improvement and performance in our pharmaceutical services development and manufacturing operations and created industry leading quality compliance and project management functions. As a result, AMRI has been able to distinguish itself in Steve's areas of responsibility in a highly competitive marketplace and continues to cement relationships with multiple customers throughout the world as a partner of choice for their development and supply of a large number of exciting new medicines. I am confident Dr. Hagen will continue to deliver the leadership that is needed in order to enhance our SMARTSOURCING™ approach while continuing to improve profitability in these business sectors. We are pleased to recognize Steve's continuing contributions to AMRI with this promotion to Senior Vice President."
Dr. Hagen joined AMRI in 2005 as senior director of analytical quality services and has risen to positions of increasing responsibility. In 2006, Dr. Hagen was promoted to vice president for quality and analytical chemistry and was responsible for Analytical Chemistry, Quality Assurance and Regulatory Affairs for all AMRI locations. In 2008, Dr. Hagen was promoted to vice president of pharmaceutical development and manufacturing.
Prior to AMRI, he spent more than 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer's Global Research and Development Division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research, Inc. in support of R&D, production and quality control. Dr. Hagen earned a Ph.D. in biochemistry and a Master's degree in botany, both from the University of Idaho, as well as a B.A. in biology from Lawrence University.
Albany Molecular Research, Inc. (AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, and manufacturing services. For over 21 years, AMRI has demonstrated its adaptability as the pharmaceutical and biotechnology industries have undergone tremendous change in response to multiple challenges. This experience, a track record of success, and locations in the United States, Europe and Asia now provides our customers with SMARTSOURCING™, a full range of value-added opportunities providing customers informed decision-making, enhanced efficiency and more successful outcomes at all stages of the pipeline. AMRI has also successfully partnered R&D programs and is actively seeking to out-license its remaining programs for further development. For press releases and additional information about the company, please visit www.amriglobal.com.